InterMune Inc. (ITMN)
-NasdaqGS 9.99 
0.31(3.01%) May 17, 4:00PM EDT|After Hours
:
9.99 0.00 (0.00%) May 17, 4:56PM EDT
| Prev Close: | 10.30 |
|---|
| Open: | 10.41 |
|---|
| Bid: | 7.87 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 14.29 |
|---|
| Beta: | 4.28 |
|---|
| Next Earnings Date: | 24-Jul-13 |
|---|
| Day's Range: | 9.94 - 10.54 |
|---|
| 52wk Range: | 7.21 - 12.77 |
|---|
| Volume: | 1,541,438 |
|---|
| Avg Vol (3m): | 1,335,400 |
|---|
| Market Cap: | 816.02M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.34 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- INTERMUNE INC FinancialsEDGAR Online Financials(Sat, May 11)
- Kyrgyzstan Decries Dismissal of U.S. Case Against Bakiyevat Bloomberg(Fri, May 10)
- U.S. Case Ends Against Ex-Kyrgyz Leader Bakiyev’s Sonat Bloomberg(Thu, May 9)
- After AbbVie's Humira: What Next?at Seeking Alpha(Mon, May 6)
- INTERMUNE INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, May 6)
- 2 Biotechs To Avoid, 1 To Buyat Motley Fool(Sat, May 4)
- Positive News in the Oncology Space Regarding Myeloma and Melanoma Drugs: Expert Analyst Boris Peaker Discusses Recent Successes for Biotechnology CompaniesWall Street Transcript(Wed, May 1)
- UPDATE 1-Europe's regulator digs in for drug data fightat Reuters(Tue, Apr 30)
- Court stops EU regulator releasing drug company dataat Reuters(Tue, Apr 30)
- ITMN Crosses Above Key Moving Average Levelat TheStreet(Mon, Apr 29)
- Sarepta (SRPT) Targets Unmet Medical Need in the Treatment of Duchenne Muscular Dystrophy; Developing First Drug with the Promise of Stopping Fatal Progressive DiseaseWall Street Transcript(Mon, Apr 29)
- Hedge funds are buying these stocksat MarketWatch(Fri, Apr 26)
- InterMune Cuts Loss, Affirms ViewZacks(Thu, Apr 25)
- InterMune's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, Apr 24)
- InterMune Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Wed, Apr 24)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 26.44 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.78 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.70 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | 0.21 |
|---|
Business Summary
InterMune, Inc., a biotechnology company, engages in the research, development, and commercialization of therapies in pulmonology and orphan fibrotic diseases.
View More